HRMY - NASDAQ

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%

HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.86B

EPS2.7600

P/E Ratio11.63

Earnings Date08/04/2026

hrmy

Total Liabilities

Last Annual Value

401.41M

3-Year CAGR

14%

5-Year CAGR

10-Year CAGR

48%

Adjust for Inflation

Harmony Biosciences Holdings, Inc. Competitors Analysis of Total Liabilities

HRMY · NASDAQ

Company	Total Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Harmony Biosciences Holdings, Inc. NASDAQ:HRMY	401.41M	5.2%	10.2%	N/A
MannKind Corporation NASDAQ:MNKD	843.20M	5.3%	9.7%	11.2%
Biohaven Ltd. NYSE:BHVN	399.38M	67.3%	53.2%	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	19.12M	-51.4%	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	55.82M	15.3%	17.3%	-7.2%
Janux Therapeutics, Inc. NASDAQ:JANX	50.70M	12.0%	30.3%	N/A
Nuvation Bio Inc. NYSE:NUVB	289.11M	160.5%	57.2%	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	130.21M	20.8%	55.9%	N/A

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $32.1

Related Guides

Blog Categories

Continue your HRMY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.